Corvus Pharmaceuticals, Inc. — 2016 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2016. The filing also reports unaudited fourth-quarter results. Corvus is a clinical-stage biopharmaceutical company developing immuno-oncology therapies; it had no product revenue.
Financial performance and position
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $29.4 million | $11.4 million |
| General and administrative expense | $7.6 million | $2.4 million |
| Total operating expenses | $37.0 million | $13.8 million |
| Net loss | $36.4 million | $31.3 million |
| Net loss per share, basic and diluted | $2.36 | $83.86 |
| Cash, cash equivalents and marketable securities, year-end | $134.9 million | $94.4 million |
| Working capital, year-end | $130.1 million | $92.6 million |
- Net cash used in operating activities was $27.9 million in 2016, versus $11.3 million in 2015. Investing activities used $42.6 million, largely reflecting purchases of marketable securities; financing activities provided $71.4 million, principally from the IPO.
- Current liabilities were $5.9 million and total liabilities were $7.3 million at year-end. The filing reports no material debt balance. Operating lease obligations totaled $4.7 million through 2021.
- No operating margin or profitability measure is meaningful because the company had no revenue and reported operating losses. The 2015 net loss included a $17.6 million noncash charge from remeasurement of a convertible preferred-stock liability; there was no comparable charge in 2016.
- Fourth-quarter 2016 operating expenses were $11.2 million and net loss was $11.1 million, compared with $6.1 million and $6.0 million, respectively, in fourth-quarter 2015.
Material changes and business developments
- Operating expenses rose $23.2 million year over year, led by increased clinical-trial and manufacturing costs for CPI-444, expansion of CPX-006 and ITK development, higher headcount, and public-company costs.
- Corvus completed its March 2016 IPO and partial overallotment, receiving approximately $70.6 million in net proceeds. Preferred shares converted into common stock. At December 31, 2016, 20.9 million common shares were outstanding.
- CPI-444’s Phase 1/1b dose-selection stage enrolled 48 patients; 47 received treatment. The company selected 100 mg twice daily for the expansion stage, which was enrolling across ten disease-specific cohorts at 36 sites.
- In results reported as of January 2017, 33 patients had reached the initial three-month assessment: there were no complete responses, two partial responses and 12 cases of stable disease. The company expanded the single-agent renal-cell-cancer cohort after meeting its protocol-defined activity criteria. These are preliminary, early-stage findings, not confirmatory efficacy results.
- CPX-006, an anti-CD73 antibody, and an ITK inhibitor were in IND-enabling studies. The company planned Phase 1 trials for both in 2018 and expected to select an A2B antagonist development candidate in 2017.
Outlook, risks and unusual items
- Management expected current cash, cash equivalents and marketable securities to cover planned expenditures and obligations for at least 12 months from the filing. It also stated that existing resources would not fund CPI-444 through commercialization; additional financing may be needed. Management anticipated continued and increasing losses.
- Clinical, regulatory and commercial outcomes remain highly uncertain. Key risks include failure to demonstrate safety or efficacy, trial delays or enrollment challenges, competition, dependence on third-party manufacturers and research providers, and limited or uncertain patent protection.
- Two serious adverse events occurred in combination-treated patients during the CPI-444 trial: Grade 3 autoimmune hemolytic anemia and Grade 4 aseptic meningoencephalitis considered potentially immune-related. Both resolved after treatment discontinuation. The filing says other reported toxicities were generally mild, but combination safety requires continued assessment.
- Corvus pays for the relevant CPI-444 collaboration studies while Genentech supplies atezolizumab. Vernalis milestone payments could total approximately $220 million across indications, in addition to royalties. A $3 million milestone payment was made in February 2017 after renal-cohort expansion; the payment is subsequent to year-end.
- Other disclosed exposures include $4.7 million of lease commitments and contingent license milestones and royalties. The company reported no material legal proceedings or off-balance-sheet arrangements.
Important facts for investors to verify
- Progress, durability and independently interpretable outcomes from CPI-444 expansion cohorts, including the renal-cell-cancer cohort and combination arm.
- Full trial safety data, especially immune-related adverse events in combination with atezolizumab, and whether they affect dosing or development plans.
- Actual cash burn and financing needs relative to the stated minimum 12-month runway and the longer path to potential commercialization.
- Timing and results of IND-enabling work and planned clinical starts for CPX-006 and the ITK candidate, plus A2B candidate selection.
- Future Vernalis milestone and royalty obligations, manufacturing concentration and supply continuity, and the scope and durability of intellectual-property rights.